Pacira BioSciences Future Growth
Future criteria checks 4/6
Pacira BioSciences is forecast to grow earnings and revenue by 29.3% and 8.1% per annum respectively. EPS is expected to grow by 28.5% per annum. Return on equity is forecast to be 16.6% in 3 years.
Key information
29.3%
Earnings growth rate
28.5%
EPS growth rate
Pharmaceuticals earnings growth | 20.7% |
Revenue growth rate | 8.1% |
Future return on equity | 16.6% |
Analyst coverage | Good |
Last updated | 04 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 833 | 115 | 260 | 313 | 10 |
12/31/2025 | 764 | 91 | 208 | 258 | 10 |
12/31/2024 | 694 | 60 | 181 | 223 | 9 |
12/31/2023 | 675 | 42 | 139 | 155 | N/A |
9/30/2023 | 666 | 7 | 130 | 149 | N/A |
6/30/2023 | 669 | -5 | 127 | 147 | N/A |
3/31/2023 | 669 | -10 | 105 | 134 | N/A |
12/31/2022 | 667 | 16 | 115 | 145 | N/A |
9/30/2022 | 654 | 21 | 93 | 126 | N/A |
6/30/2022 | 614 | 39 | 102 | 144 | N/A |
3/31/2022 | 580 | 38 | 104 | 144 | N/A |
12/31/2021 | 542 | 42 | 80 | 126 | N/A |
9/30/2021 | 513 | 62 | 98 | 149 | N/A |
6/30/2021 | 503 | 174 | 83 | 129 | N/A |
3/31/2021 | 443 | 148 | 39 | 83 | N/A |
12/31/2020 | 430 | 146 | 39 | 77 | N/A |
9/30/2020 | 421 | 126 | 28 | 56 | N/A |
6/30/2020 | 408 | -10 | 13 | 35 | N/A |
3/31/2020 | 435 | 0 | 58 | 73 | N/A |
12/31/2019 | 421 | -11 | 60 | 71 | N/A |
9/30/2019 | 394 | 2 | 58 | 66 | N/A |
6/30/2019 | 372 | 8 | 53 | 64 | N/A |
3/31/2019 | 354 | 7 | 44 | 55 | N/A |
12/31/2018 | 337 | 0 | 34 | 49 | N/A |
9/30/2018 | 321 | -4 | 27 | 45 | N/A |
6/30/2018 | 305 | -11 | 7 | 25 | N/A |
3/31/2018 | 292 | -33 | -6 | 15 | N/A |
12/31/2017 | 287 | -43 | -1 | 18 | N/A |
9/30/2017 | 280 | -51 | N/A | 18 | N/A |
6/30/2017 | 281 | -66 | N/A | 33 | N/A |
3/31/2017 | 280 | -54 | N/A | 37 | N/A |
12/31/2016 | 276 | -38 | N/A | 33 | N/A |
9/30/2016 | 273 | -36 | N/A | 33 | N/A |
6/30/2016 | 267 | -11 | N/A | 26 | N/A |
3/31/2016 | 256 | -3 | N/A | 26 | N/A |
12/31/2015 | 249 | 2 | N/A | 28 | N/A |
9/30/2015 | 241 | 10 | N/A | 26 | N/A |
6/30/2015 | 231 | 4 | N/A | 29 | N/A |
3/31/2015 | 219 | -1 | N/A | 30 | N/A |
12/31/2014 | 198 | -14 | N/A | 27 | N/A |
9/30/2014 | 169 | -31 | N/A | 6 | N/A |
6/30/2014 | 141 | -43 | N/A | -13 | N/A |
3/31/2014 | 111 | -52 | N/A | -34 | N/A |
12/31/2013 | 86 | -64 | N/A | -44 | N/A |
9/30/2013 | 62 | -68 | N/A | -58 | N/A |
6/30/2013 | 48 | -69 | N/A | -59 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 82P's forecast earnings growth (29.3% per year) is above the savings rate (0.6%).
Earnings vs Market: 82P's earnings (29.3% per year) are forecast to grow faster than the German market (15.1% per year).
High Growth Earnings: 82P's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 82P's revenue (8.1% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 82P's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 82P's Return on Equity is forecast to be low in 3 years time (16.6%).